Compare · EAF vs TMO
EAF vs TMO
Side-by-side comparison of GrafTech International Ltd. (EAF) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- EAF operates in Energy, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $183.60B, about 695.1x EAF ($264.1M).
- Over the past year, EAF is up 0.9% and TMO is up 24.5% - TMO leads by 23.6 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 10 for EAF).
- TMO has more recent analyst coverage (25 ratings vs 6 for EAF).
- Company
- GrafTech International Ltd.
- Thermo Fisher Scientific Inc
- Price
- $10.19+3.66%
- $493.55+0.20%
- Market cap
- $264.1M
- $183.60B
- 1M return
- +19.04%
- +2.96%
- 1Y return
- +0.89%
- +24.50%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 10
- 17
- Recent ratings
- 6
- 25
GrafTech International Ltd.
GrafTech International Ltd. researches, develops, manufactures, and sells graphite and carbon based products worldwide. It offers graphite electrodes to produce electric arc furnace steel and other ferrous and non-ferrous metals; and petroleum needle coke, a crystalline form of carbon used in the production of graphite electrodes. The company sells its products primarily through direct sales force, independent sales representatives, and distributors. GrafTech International Ltd. was founded in 1886 and is headquartered in Brooklyn Heights, Ohio.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest EAF
- SEC Form 8-K filed by GrafTech International Ltd.
- SEC Form 424B5 filed by GrafTech International Ltd.
- SEC Form EFFECT filed by GrafTech International Ltd.
- GrafTech Announces Publication of 2025 Sustainability Report
- SEC Form S-3 filed by GrafTech International Ltd.
- SEC Form 4 filed by Director Germain Jean-Marc
- SEC Form 4 filed by Director Shivaram Sachin M
- SEC Form 4 filed by Director Fine Debra
- SEC Form 4 filed by Director Roegner Eric V
- SEC Form 4 filed by Director Keizer Henry R.
Latest TMO
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)
- Director Johnson Jennifer M was granted 499 shares, increasing direct ownership by 55% to 1,403 units (SEC Form 4)
- Director Jacks Tyler was granted 499 shares, increasing direct ownership by 6% to 9,462 units (SEC Form 4)